Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andrew D. Gewitz
Observed names:
Andrew D Gewitz,
Andrew Gewitz
Institution:
Kyowa Kirin (United States)
Observed institutions:
University of California, San Francisco,
Regeneron (United States),
Kyowa Kirin (United States),
Stanford University
ORCID:
0009-0005-5362-5324
Observed ORCID:
0009-0005-5362-5324
OpenAlex ID:
A5059751620
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial
2023
·
Robert S. Rosenson
, Daniel Gaudet
, et al.
·
Nature Medicine
·
145
PDF
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors
2017
·
Mallika S. Dhawan
, Imke H. Bartelink
, et al.
·
Clinical Cancer Research
·
79
Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency
2023
·
Judith Y. Altarejos
, Jeffrey Pangilinan
, et al.
·
Science Translational Medicine
·
26
Relational grounding facilitates development of scientifically useful multiscale models
2011
·
C Anthony Hunt
, Glen EP Ropella
, et al.
·
Theoretical Biology and Medical Modelling
·
23
PDF
Longitudinal Model-Based Biomarker Analysis of Exposure-Response Relationships in Adults with Pulmonary Tuberculosis
2021
·
Andrew D. Gewitz
, Belén P. Solans
, et al.
·
Antimicrobial Agents and Chemotherapy
·
11
Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first‐in‐human phase I study
2024
·
Andrew Gewitz
, Jeanne Mendell
, et al.
·
Clinical and Translational Science
·
10
Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody
2025
·
Hiroki Okada
, Sam Liao
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
PDF
† Pharmacokinetics of Mibavademab in Healthy Participants: Results from a Randomized, Phase 1, Two-Part, First-in-Human Study
2023
·
Jeanne Mendell
, Andrew Gewitz
, et al.
·
Journal of clinical lipidology
Supplementary Figures and Text from Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors
2023
·
Mallika S. Dhawan
, Imke H. Bartelink
, et al.
Data from Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors
2023
·
Mallika S. Dhawan
, Imke H. Bartelink
, et al.
Synthetic Models and Methods
2013
·
C. Anthony Hunt
, Andrew D. Gewitz
, et al.
·
Springer eBooks
Show more works
View as search
Works count:
11
Citation count:
294
H-index:
6
I10-index:
6
Year
Topic
Type
